Thursday, December 6, 2012
Got some promising news on the c-met drug front. A new drug called cabozantinib (Cometriq) was just approved by the FDA on November 29th, 2012. This is the second drug that's FDA approved that's a c-met protein inhibitor. Cabozantinib is going to now be prescribed as treatment for medullary thyroid cancer (MTC). The drug company, Exelis, is currently studying cabozantinib as treatment for prostate cancer too. I've been doing some research and there's strong opinion that once it is FDA approved for prostate cancer, that oncologists will be able to prescribe this for any cancers with c-met expression in tumors. This is something that will really benefit a lot of patients out there.
In the meantime, I've already bugged Dr. A about getting the ball rolling on seeing how we can get off-label usage for cabozantinib. So, it's in the works along with crizotinib (the lung cancer c-met inhibitor) which we've filed an appeal to the insurance company. We're awaiting the appeal decision.
If both of these pathways don't pan out, I'll be heading to Detroit with mom somehow. Not sure how yet, but that'll be our last option. Not giving up.